In more detail, this approach was applied to the H1650 and HCC827 human lung cancer cell lines that displayed different responsiveness to gefitinib, an EGFR tyrosine kinase inhibitor, due to an EGFR Exon 19 mutation. This evidence concerns the gene EGFR and lung cancer.